Published one-year data from the two multicentre double-blind studies VIEW 1 and VIEW 2 (total pts=2,419) of the new anti-VEGF and anti-PIGF drug Aflibercept (Eylea®) in the treatment of wet AMD.
The results show that after three initial monthly doses, an intravitreal injection of aflibercept 2 mg given every two months is as effective as a monthly injection of ranibizumab in containing visual loss below 15 letters.
The most frequent adverse reactions (?5%) were conjunctival haemorrhages, ocular pain, cataracts, vitreous detachment, myodesopsies and increased ocular pressure.
The safety profile of the new drug was similar to that of ranibizumab, including the incidence of cardiovascular events.
The advantages of bi-monthly administration of aflibercept could be: reduced risk compared to intravitreal injection every 4 weeks and the associated costs of monthly monitoring.
See the article published in Ophthalmology of October 2012.
Dr. Carmelo Chines
Direttore responsabile
English 
Italian